Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
VolitionRx Limited
VNRX | US
0.73
USD-0.00
-0.25%
VNRX | US
About VolitionRx Limited
Sector
Healthcare
Industry
Diagnostics & Research
Earnings date
30/06/2024
As of date
21/10/2024
Close
0.73
Open
0.72
High
0.75
Low
0.70
VolitionRx Limited a multi-national epigenetics company engages in the development of blood tests to help diagnose and monitor a range of cancers and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover a solution to profiling nucleosomes. The company is based in Henderson Nevada.
View LessVNRX | US
Risk
127.3
Sharpe
-0.16
Luna's Score
49/100
Recommendation
Hold
Luna says (VNRX | US)
What's Working
Positive Momentum
Low Debt to Equity (< 0.25)
Strong Revenue Growth (> 10%)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
71.6%1 month
127.3%3 months
98.4%6 months
108.2%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
38.44
Debt to equity
-0.27
Debt to assets
0.45
Ent. to EBITDA
-1.43
Ent. to rev.
68.97
PEG
-
Other Fundamentals
EBITDA
-31.64M
MarketCap
67.33M
MarketCap(USD)
67.33M
Div. yield
-
Op. margin
-1.77K
Erngs. growth
-
Rev. growth
83.00
Ret. on equity
-730.06
Short ratio
4.25
Short perc.
0.59
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.22
Range1M
0.34
Range3M
0.47
Volumes: Market Activity
Rel. volume
0.74
Price X volume
59.58K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.43 | - | Cheaper |
| Ent. to Revenue | 68.97 | - | Expensive |
| PE Ratio | - | 40.09 | - |
| Price to Book | 38.44 | 77.50 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 98.43 | - | Riskier |
| Debt to Equity | -0.27 | -14.36 | Expensive |
| Debt to Assets | 0.45 | 0.34 | Expensive |
| Market Cap | 67.33M | - | Emerging |
